SYRS Profile
Syros Pharmaceuticals Inc. (SYRS) is a biopharmaceutical company focused on developing medicines that control the expression of genes that cause diseases. SYRS uses its proprietary gene control platform, called gene control, to identify gene networks that become dysregulated in diseases such as cancer, sickle cell disease, and beta-thalassemia, among others. The company aims to develop a pipeline of first-in-class drug candidates that target these gene networks and that can modulate the expression of disease-causing genes.
SYRS is headquartered in Cambridge, Massachusetts, and was founded in 2011. The company went public in 2016 and is traded on the NASDAQ stock exchange under the ticker symbol SYRS.
SYRS' lead drug candidate is called SY-1425, which is being developed as a treatment for acute myeloid leukemia (AML) and other blood cancers. SY-1425 is an oral, small-molecule inhibitor of a protein called RARA, which is overexpressed in AML and other blood cancers. By inhibiting RARA, SY-1425 can restore normal gene expression patterns in cancer cells, leading to cancer cell death.
SYRS is also developing other drug candidates that target gene networks implicated in other diseases, including solid tumors, sickle cell disease, and beta-thalassemia. These drug candidates are in various stages of preclinical and clinical development.
Overall, SYRS is focused on developing medicines that can modulate the expression of disease-causing genes and that can treat a wide range of diseases, including cancer, sickle cell disease, and beta-thalassemia, among others. The company's proprietary gene control platform allows it to identify gene networks that are dysregulated in diseases and to develop drug candidates that can modulate the expression of these genes. SYRS' lead drug candidate, SY-1425, is being developed as a treatment for AML and other blood cancers, and the company is also developing other drug candidates that target gene networks implicated in other diseases.
|
